Aprea Therapeutics updates shareholders on clinical programs and 2026 outlook

Aprea Therapeutics Inc. (NASDAQ: APRE) provided shareholders with an update on its clinical pipeline progress and financial position through a letter from Chief Executive Officer Oren Gilad.

The company reported continued enrollment in its ACESOT-1051 dose-escalation study for lead drug candidate APR-1051, a WEE1 inhibitor, with patients currently enrolled in the 220 mg cohort. Through the 150 mg dose level, the treatment showed no dose-limiting toxicities or unexpected safety issues. The company observed disease stabilization in several patients, with the longest treatment duration reaching 222 days and a notable 15% reduction in tumor burden in one case.

Aprea amended its clinical protocol to increase enrollment of patients with HPV-positive head and neck cancer after observing encouraging activity at the 70 mg dose level. The company expects to report additional safety and efficacy data in the first quarter of 2026 and complete dose escalation during 2026.

For its ATR inhibitor program ATRN-119, Aprea reached the recommended Phase 2 dose for once-daily dosing but paused further enrollment in monotherapy arms to focus on combination therapy strategies. The company cited cash preservation in a challenging fundraising environment as a factor in this decision.

The biopharmaceutical company completed a $3.1 million gross private placement financing, which it projects will extend its cash runway into the first quarter of 2027. CEO Gilad, the chief financial officer, and a board member participated in the financing alongside external investors including healthcare-focused funds and existing shareholders.

Aprea is developing treatments that target cancer cell vulnerabilities while minimizing damage to healthy cells, with potential applications across multiple cancer types including ovarian, endometrial, colorectal, prostate, and breast cancers.

You May Also Be Interested In

• Sanuwave Q2 2026 revenue tops revised guidance range
• Microvision (MVIS) files $50M mixed shelf
• Honeywell Aerospace launches $16B note exchange offer